You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)子公司華潤三九獲治療腦膠質瘤新藥大中華區獨家授權
阿思達克 12-18 11:01
華潤醫藥(03320.HK)公布,旗下子公司華潤三九與Oncoceutics達成授權合作,華潤三九獲得腦膠質瘤創新藥產品「ONC201」在大中華區(中國大陸、香港、澳門、台灣)的獨家開發、生產及商業化權益。

集團指,Oncoceutics是一家臨床階段藥物發現和開發公司,擁有一類名為imipridones的新型化合物,可選擇性地靶向G蛋白偶聯受體用於腫瘤治療。ONC201是一種口服活性小分子DRD2拮抗劑和ClpP激動劑,作為Oncoceutics開發的核心產品,目前處於關鍵性臨床階段,是一種具有獨特作用機制的新型小分子,已在多項臨床試驗中證明瞭其抗癌活性和安全性,其中包括對高級別膠質瘤成人和兒童患者的臨床試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account